Keeping Covax cool
Keeping Covax cool
Scientists across the globe are working on a vaccine for Covid-19, which will have to be kept cold during transit to preserve its viability … Thermo King has expanded its portfolio of temporary storage solutions to assist this endeavour.
Pharmaceutical companies in final-stage clinical trials anticipate they will require strict temperature controls to safeguard their products – down to temperatures as low as -70°C.
According to the World Health Organization, nearly 20% of temperature-sensitive health care products are damaged during transport, and 25% of vaccines reach their destination in a degraded state due to breaks in the cold chain.
“Considering the urgent global need for a Covid-19 vaccine, the world can’t afford breaks in the cold chain,” says Dave Regnery, president and chief operating officer of Trane Technologies (provider of the end-to-end temperature-controlled cold chain solutions provider, Thermo King).
“Our new cold storage solutions can maintain temperatures of -70°C for an extended period, can be leveraged to help reduce degradation of a vaccination, and most importantly, could prevent vaccine ‘deserts’ or lack of accessibility.”
Thermo King and its worldwide partners can also offer security and traceability through its telematics. Additional storage solutions include refrigerated trailers, containers and portable cubes that can easily be scaled and repositioned to other locations as demand changes.
In addition to launching cold storage solutions, Thermo King has helped customers identify ways to maximise the range of dry ice, which is often used in vaccine transport and storage but has certain limitations.
A container using dry ice to keep a product frozen may require re-icing if it sits for an extended length of time or is exposed to extreme ambient weather. Thermo King offers storage solutions that can substantially extend the life of dry ice, or eliminate the need altogether.
“We have been engaging pharmaceutical and transport companies, policymakers, regulators and other industry partners to discuss ways to strengthen the cold chain,” says Regnery. “We know that we can help mitigate risk – we have a long history in cold chain expertise, and are actively working to innovate and address the complexities and potential challenges of the mass distribution of a temperature-sensitive vaccine.”